DPQ

DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD⁺/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases^[1][2][3]. IC50 & Target:PARP-1^[1] In Vitro:DPQ (10 μM; pretreatment 30 min, treatment 2-8 h) significantly inhibits the mRNA expression of TNF-α, IL-1β, IL-6, CXCL-1, MIP-2 and iNOS in mouse peritoneal macrophages stimulated by LPS (100 ng/mL) ^[2].

DPQ (10 μM; pretreatment 30 min, treatment 2-8 h) inhibits the degradation of IkB-α and phosphorylation of NF-κB p65 in macrophages induced by LPS (100 ng/mL)，blocking the inflammatory signaling pathway^[2].
In Vivo:DPQ (10 mg/kg; intraperitoneal injection; single dose; 6 h) significantly attenuates lung inflammation, neutrophil infiltration, and vascular leakage in LPS-induced acute lung injury model of C57BL/6 mice, inhibiting NF-κB pathway activation^[2].
DPQ (10 mg/kg; intraperitoneal injection; single dose; 4 weeks) improves cardiac function and reduced apoptosis and oxidative stress in myocardial infarction model of Wistar rats^[3].